Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007

Seelos Therapeutics Announces Update to Parkinson’s Disease Program SLS-007
Delivery of SLS-007 to Utilize an Adeno-Associated Virus (AAV) Vector SLS-007 to Become Seelos’ Second Gene Therapy Program Focused on Parkinson’s NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos ... read more
Source: Bing NewsPublished on 2020-01-28